Current and emerging systemic treatment strategies for psoriasis (Q38039491)

27 August 2017

Current and emerging systemic treatment strategies for psoriasis (English)

1 reference

27 August 2017

Philip M Laws

1

1 reference

PubMed ID

22938141

27 August 2017

Helen S Young

series ordinal

2

1 reference

27 August 2017

1 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

72

1 reference

27 August 2017

14

1 reference

27 August 2017

1867-1880

1 reference

https://scigraph.springernature.com/pub.10.2165/11634980-000000000-00000

27 August 2017

0 references

cites work

Pathogenesis and clinical features of psoriasis

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

A classification of psoriasis vulgaris according to phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Quality of life in patients with psoriasis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Topical treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Methotrexate in psoriasis: consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Ciclosporin in psoriasis clinical practice: an international consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Efficacy and safety of oral retinoids in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Treatment of psoriasis with oral liarozole: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Concurrent use of methotrexate and acitretin revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Combining traditional agents and biologics for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLS

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Patented small molecules against psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Therapeutic targeting of Janus kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Treating inflammation with the Janus kinase inhibitor CP-690,550.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Targeting protein kinases for the development of anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Activation of protein kinase C isoforms and its impact on diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Protein kinase C isoforms in neutrophil adhesion and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Sirtuin activators: designing molecules to extend life span.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

The alliance of sphingosine-1-phosphate and its receptors in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634980-000000000-00000

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis

21 January 2018

1 reference

12 December 2020

Medical comorbidity associated with psoriasis in adults: a population-based study

1 reference

12 December 2020

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

1 reference

12 December 2020

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

12 December 2020

Long-term cyclosporine in the management of psoriasis

1 reference

12 December 2020

Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study

1 reference

12 December 2020

Psoriasiform drug eruption due to abatacept

1 reference

12 December 2020

Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study

1 reference

12 December 2020

Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation

1 reference

12 December 2020

Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris

1 reference

12 December 2020

Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial

1 reference

12 December 2020

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

1 reference

12 December 2020

Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment

1 reference

12 December 2020

Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies

1 reference

12 December 2020

Abatacept-induced psoriasis

1 reference

12 December 2020

Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy

1 reference

12 December 2020

Complementary roles for CD2 and LFA-1 adhesion pathways during T cell activation

1 reference

12 December 2020

Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection

1 reference

12 December 2020

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

1 reference

12 December 2020

Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial

1 reference

12 December 2020

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

12 December 2020

The editor's roundtable: psoriasis, inflammation, and coronary artery disease

1 reference

12 December 2020

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

1 reference

12 December 2020

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

12 December 2020

The genetics of psoriasis, psoriatic arthritis and atopic dermatitis

1 reference

12 December 2020

Methotrexate and ciclosporin combination for the treatment of severe psoriasis

1 reference

12 December 2020

[Treatment of psoriasis vulgaris.]

1 reference

12 December 2020

Cyclosporine as maintenance therapy in patients with severe psoriasis

1 reference

12 December 2020

Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India

1 reference

12 December 2020

Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indication

1 reference

12 December 2020

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis

1 reference

12 December 2020

Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study

1 reference

12 December 2020

Topical cyclosporin A in psoriasis

1 reference

12 December 2020

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

1 reference

12 December 2020

10.2165/11634980-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22938141

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

22938141